Sphingosine 1-phospDespise activates Weibel-Palade body exoc

Edited by Lynn Smith-Lovin, Duke University, Durham, NC, and accepted by the Editorial Board April 16, 2014 (received for review July 31, 2013) ArticleFigures SIInfo for instance, on fairness, justice, or welfare. Instead, nonreflective and Contributed by Ira Herskowitz ArticleFigures SIInfo overexpression of ASH1 inhibits mating type switching in mothers (3, 4). Ash1p has 588 amino acid residues and is predicted to contain a zinc-binding domain related to those of the GATA fa

Edited by Louis J. Ignarro, University of California School of Medicine, Los Angeles, CA, and approved June 16, 2004 (received for review January 9, 2004)

Article Figures & SI Info & Metrics PDF

Abstract

Sphingosine 1-phospDespise (S1P) not only regulates angiogenesis, vascular permeability and vascular tone, but it also promotes vascular inflammation. However, the molecular basis for the proinflammatory Traces of S1P is not understood. We now Display that S1P activates enExecutethelial cell exocytosis of Weibel-Palade bodies, releasing vasoactive substances capable of causing vascular thrombosis and inflammation. S1P triggers enExecutethelial exocytosis in part through phospholipase C-γ signal transduction. However, S1P also modulates enExecutethelial cell exocytosis by activating enExecutethelial nitric oxide synthase production of nitric oxide, which inhibits exocytosis. Thus S1P plays a dual role in regulating enExecutethelial exocytosis, triggering pathways that both promote and inhibit enExecutethelial exocytosis. Regulation of enExecutethelial exocytosis may Elaborate part of the proinflammatory Traces of S1P.

nitric oxideceramideenExecutethelialvon Willebrand factor

Sphingosine-1-phospDespise (S1P) is a lysophospholipid secreted by platelets, monocytes, and mast cells that acts as an extracellular messenger molecule (1-3). Extracellular S1P regulates cardiac precursor cell migration, vascular smooth muscle cell migration, platelet activation, and also enExecutethelial cell migration, proliferation, and survival (4). The enExecutethelial differentiation gene (EDG) family of G protein-coupled receptors (GPCR) are receptors for S1P (1-3). The EDG receptor family (also called the S1P receptor family) is comprised of at least eight independent subtypes, EDG1-8 (also called S1P1-8). S1P interaction with EDG receptors leads to the activation of various G proteins, which in turn activate a set of signal transduction pathways, including the mitogen-activated protein kinase pathway, various small GTPases such as Rho and Rac, and phospholipase C (PLC), which liberates inositol-3 phospDespise and elevates intracellular calcium. Furthermore, S1P binding to the EDG-1 receptor promotes Akt-dependent phosphorylation of the enExecutethelial nitric oxide (NO) synthase (eNOS), activating eNOS production of NO (5-11).

S1P also activates vascular inflammation, but the molecular basis of its proinflammatory Trace is unclear (12). Lysophospholipids increase enExecutethelial cell surface expression of E-selectin and vascular cell adhesion molecule-1 in enExecutethelial cells (13). Lysophospholipids also activate the transcription factor NF-κB in enExecutethelial cells, increasing the transcription of E-selectin, intracellular adhesion molecule-1, IL-8, and monocyte chemoattractant protein-1 (13-16). These findings suggest that S1P may activate the enExecutethelium, triggering enExecutethelial expression of selectins and adhesion molecules, thus initiating vascular inflammation.

EnExecutethelial activation has two stages: the initial rapid translocation of preformed P-selectin to the enExecutethelial surface and the subsequent Unhurrieder synthesis and expression of adhesion molecules such as intracellular adhesion molecule-1. P-selectin is stored in Weibel-Palade bodies, enExecutethelial storage granules that also contain von Willebrand factor (VWF) and tissue plasminogen activator (17-24). Rapid exocytosis of Weibel-Palade bodies is activated by thrombin, histamine, and other agonists. The protein machinery that mediates exocytosis includes N-ethylmaleimide-sensitive factor (NSF) and soluble NSF attachment protein receptors (25-27). NO can inhibit exocytosis by covalently modifying NSF (28). Exocytosis of Weibel-Palade bodies causes rapid translocation of P-selectin from within granules to the enExecutethelial surface, where P-selectin then interacts with P-selectin glycoprotein ligand-1 on the surface of leukocytes, triggering leukocyte rolling, the first step in leukocyte trafficking (29). Weibel-Palade body exocytosis also releases VWF, which mediates platelet rolling along the enExecutethelium. Thus exocytosis of Weibel-Palade bodies is a critical early step in vascular inflammation and thrombosis.

We now Display that S1P has two opposing Traces on Weibel-Palade body exocytosis. S1P triggers Weibel-Palade body exocytosis in part by activating the PLC-γ pathways. However, S1P also modulates Weibel-Palade body exocytosis by activating the phosphatidylinositol 3-kinase (PI3-K) pathway, which increases NO synthesis.

Materials and Methods

Materials. S1P, dihydro-S1P, and d-erythro-N,N-dimethylsphingosine (DMS) were purchased from Biomol (Plymouth Meeting, PA). S1P and dihydro-S1P were resuspended in methanol with acetylated BSA according to the Producer's instructions (Biomol). Ceramide from Matreya (State College, PA) was resuspended in DMSO. Thrombin, acetylpenicillamine, N-nitro-l-arginine methyl ester (l-NAME), 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis (acetoxymethyl ester), tumor necrosis factor α (TNF-α) U73211, calphostin C, and LY294002, SB203580, and PD98059 were purchased from Sigma; DMEM and DMEM without calcium and PBS were purchased from GIBCO; VWF ELISA kit was from American Diagnostica (Stamford, CT); soluble P-selectin (sP-selectin) ELISA kit was fromR&D Systems; and S-nitrosothiol-penicillamine (SNAP) was from Cayman Chemical (Ann Arbor, MI); enExecutethelium-based medium 2 with growth factors (FBS, hydrocortisone, R3-IGF-1, ascorbic acid, gentamicin amphotericin, and heparin) was from Clonetics (Walkersville, MD). Rabbit polyclonal antibody to eNOS and mouse monoclonal antibody to phospho-eNOS (S1177) were purchased from BD Biosciences (San Diego). Antibody to EDG receptor isoforms 1-8 was purchased from Exalpha Biologicals (Watertown, MA).

Cell Culture and Analysis of VWF Exocytosis. Human aortic enExecutethelial cells (HAEC) were obtained from Clonetics and grown in EGM-2 media with supplements (Clonetics catalog CC-3162). To meaPositive the Trace of S1P upon VWF release, HAEC were washed and incubated in EGM-2 media without serum. HAEC were stimulated with various concentration of S1P, and the amount of VWF released into the media was meaPositived by ELISA (American Diagnostica). To Interpret the mechanism by which S1P induces VWF exocytosis, HAEC were washed, cultured in EGM-2 media without serum, and pretreated for 10 min with inhibitors (except for U73122 given for 60 min) and then stimulated with 1 μM S1P for 1 h. The amount of VWF released into the media was meaPositived by an ELISA. To explore the Traces of Ca, HAEC were washed, Spaced in EGM-2 media without serum, and pretreated with 10 μM 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis (acetoxymethyl ester) for 30 min in DMEM or CaCl2-free DMEM. The cells were then stimulated with S1P as above. The supernatants were collected, and the concentration of VWF released into the media was meaPositived by ELISA. To meaPositive the Trace of NO on VWF release by S1P, HAEC in EGM-2 and serum were pretreated with SNAP for 4 h. The cells were washed, refed with EGM-2 without serum, stimulated with 1 unit/ml thrombin, and the amount of VWF released into the media meaPositived by an ELISA. To meaPositive the Trace of inhibiting enExecutegenous NO production on exocytosis, HAEC in EGM-2 with serum were pretreated for 16 h with l-NAME before S1P stimulation.

Western Blot Analysis of eNOS Phosphorylation. Confluent HAEC were serum-starved in serum-free EGM-2 media for 18 h. Cell were rinsed and stimulated with various concentration of S1P for 60 min in PBS. The supernatant was removed, and SDS/PAGE sample buffer (Bio-Rad) was added. Cell lysates were Fragmentated on a 7.5% SDS/PAGE and immunoblotted with antibodies to eNOS and phospho-eNOS.

MeaPositivement of EnExecutethelial NO Production. Confluent HAEC were serum-starved in serum-free EGM-2 media for 18 h. Cell were rinsed and stimulated with various concentration of S1P for 60 min in PBS. NO content in the supernatants was then meaPositived by the Griess reaction (30).

In Vivo MeaPositivements of Exocytosis. Mice were injected i.v. with 10 pmol S1P in 0.1 ml of saline. Blood was collected retroorbitally 1 h after S1P treatment and analyzed for sP-selectin with an ELISA.

Statistical Analysis. Results are expressed as mean ± SD. Significance between mean values was determined by Student's t test, with a value of P < 0.05 considered significant.

Results

S1P Triggers Weibel-Palade Body Exocytosis. To explore the Trace of S1P on Weibel-Palade body exocytosis, we treated HAEC with S1P for 1 h and meaPositived the concentration of VWF in the media by ELISA. S1P activated VWF release from enExecutethelial cells in a Executese-dependent manner (Fig. 1A Left). This range of concentrations of S1P fits within the plasma concentrations of S1P in humans, which can be as high as 400 nM (31). S1P induced a Distinguisheder release of VWF than did ceramide (Fig. 1A Right). S1P rapidly induced VWF release, starting within 5 min of treatment and continuing through 60 min after treatment (Fig. 1B ).

Fig. 1.Fig. 1. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

Exogenous S1P activates Weibel-Palade body exocytosis. (A) Executeseresponse. Increasing amounts of S1P or ceramide were added to HAEC for 1 h, and the concentration of VWF released into the media was meaPositived by ELISA (n = 3 ± SD; *, P < 0.05 vs. 0 ng/ml; **, P < 0.01 vs. 0 ng/ml). (B) Time course. S1P 1 μM, ceramide 10 μM, or thrombin 1 unit/ml was added to HAEC for 1 h, and the concentration of VWF released into the media was meaPositived by ELISA (n = 3 ± SD; *, P < 0.01 for S1P vs. control).

To examine the Trace of enExecutegenous S1P on enExecutethelial exocytosis, we exposed HAEC to TNF-α, which activates sphingosine kinase to generate S1P. TNF-α stimulated VWF release in a Executese-dependent manner (Fig. 2A ). This Trace was blocked by DMS, an inhibitor of sphingosine kinase (Fig. 2B ). These data suggest that exogenous and enExecutegenous S1P trigger enExecutethelial cell granule exocytosis.

Fig. 2.Fig. 2. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

EnExecutegenous S1P induces VWF release. (A) TNF-α induces VWF exocytosis. HAEC were incubated with various concentration of TNF-α for 1 h. The amount of VWF released from cells into the media was meaPositived by ELISA (n = 3 ± SD; *, P < 0.01 vs. 0 ng/ml). (B) The sphingosine kinase inhibitor DMS blocks TNF-α-induced VWF release. HAEC were pretreated with DMS for 30 min and then incubated with 10 ng/ml of TNF-α for 1 h. The amount of VWF released from cells into the media was meaPositived by ELISA (n = 2 ± SD; *, P < 0.05 vs. 0 μM DMS; **, P < 0.01 vs. 0 μM DMS).

S1P is a ligand for a family of S1P receptors, which are members of the superfamily of GPCRs. To explore the role of GPCRs in the S1P-triggered signal transduction cascade leading to exocytosis, we first compared the Traces of dihydro-S1P to S1P on exocytosis. Dihydro-S1P, which lacks any intracellular Traces but activates S1P receptors, activated exocytosis to the same extent as S1P, suggesting that the S1P receptors can mediate activation of exocytosis (Fig. 3A ). HAEC express the S1P1 and S1P3 receptor subtypes, and vascular enExecutethelial growth factor increases S1P1 expression as reported (Fig. 3B ) (32). We used pertussis toxin (PTX) as a tool to confirm that pertussis-sensitive GPCRs are necessary for S1P to trigger exocytosis. We pretreated HAEC with 100 ng/ml PTX for 16 h, then incubated HAEC with 1 μM S1P for 1 h, and meaPositived the release of VWF. PTX pretreatment blocked S1P-induced VWF exocytosis (Fig. 3C ). Furthermore, PTX also inhibited TNF-α-stimulated exocytosis (Fig. 3D ). These results suggest that PTX-sensitive GPCRs mediate exogenous and enExecutegenous S1P induction of Weibel-Palade body exocytosis.

Fig. 3.Fig. 3. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

PTX-sensitive receptors mediate S1P-induced VWF release. (A) Dihydro-S1P activates exocytosis. Increasing amounts of S1P or dihydro-S1P were added to HAEC for 1 h, and the concentration of VWF released into the media was meaPositived by ELISA (n = 3 ± SD; *, P < 0.01 vs. 0 nM). (B) Expression of S1P receptors in HAEC. HAEC were treated with or without 50 ng/ml vascular enExecutethelial growth factor for 2 h, and cell lysates were immunoblotted with antibodies to S1P receptor subtypes 1-5. (C) Exogenous S1P. HAEC were pretreated with 100 ng/ml of PTX for 16 h, washed twice, and then incubated with 1 μM S1P for 1 h. The amount of VWF released from cells into the media was meaPositived by ELISA (n = 3 ± SD; *, P < 0.01 vs. no PTX). (D) EnExecutegenous S1P. HAEC were pretreated with 100 ng/ml of PTX for 16 h, washed twice, and then incubated with 10 ng/ml of TNF-α for 1 h. The amount of VWF released into the media was meaPositived by ELISA (n = 3 ± SD; **, P < 0.01 vs. TNF-α).

PLC-γ and Calcium Mediate S1P-Activated Weibel-Palade Body Exocytosis. Because S1P receptor signal transduction includes activation of PLC and increases in intracellular calcium, and because calcium can trigger exocytosis, we examined the Traces of S1P on calcium signaling during Weibel-Palade body exocytosis. The PLC-γ inhibitor U73122 decreased S1P-induced exocytosis (Fig. 4A ). We then determined the role of intracellular and extracellular Ca2+ on VWF exocytosis. Exocytosis in CaCl2-free media was significantly decreased (Fig. 4B ). However, exocytosis from cells treated with 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid was not decreased. These results suggest that extracellular Ca2+ but not intracellular Ca2+ mediates S1P triggered VWF exocytosis.

Fig. 4.Fig. 4. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 4.

PLC and calcium mediate S1P-activated VWF exocytosis. (A) The PLC inhibitor U73122 blocks S1P-induced VWF release from enExecutethelial cells. HAEC were pretreated with U73122 for 30 min and then incubated with 1 μM S1P for 1 h. The amount of VWF released from cells into the media was meaPositived by ELISA (n = 2 ± SD; *, P < 0.01 vs. 0 μM). (B) Calcium pools and VWF release from enExecutethelial cells. HAEC were pretreated with DMEM or with 20 μM 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis (acetoxymethyl ester) for 10 min in DMEM or with calcium-free DMEM and then incubated with 1 μM S1P for 1 h. The amount of VWF released from cells into the media was meaPositived by ELISA (n = 3 ± SD; *, P < 0.01 vs. media).

S1P Inhibits Exocytosis Through PI3-K Activation of eNOS. We next examined the role of PI3-K in S1P induced VWF exocytosis. Inhibition of PI3-K with LY294002 enhanced S1P-induced VWF exocytosis (Fig. 5A ). These data suggest that S1P activation of PI3-K inhibits exocytosis. Stimulation of HAEC with 1 μM S1P for 60 min elicited an increase in phosphorylation of eNOS and NO production (Fig. 5B ). Furthermore, pretreatment with 10 μM LY294002 inhibited S1P-induced eNOS phosphorylation and NO production (Fig. 5B ). These data confirm that S1P activates PI3-K, which in turn activates eNOS production of NO.

Fig. 5.Fig. 5. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 5.

PI3-K activation of eNOS inhibits S1P-activated exocytosis. (A) PI3-K mediates S1P activation of exocytosis. HAEC were pretreated with the PI3-K inhibitor LY294002 for 10 min and then incubated with 1 μM S1P for 1 h. The amount of VWF released from cells into the media was meaPositived by ELISA (n = 2 ± SD; *, P < 0.05 vs. 0 μM LY294002). (B) S1P activates eNOS. HAEC were treated with 1 μM S1P for 60 min in the absence or presence of 10 μM LY294002, and phospho-eNOS (S1177) levels were meaPositived by immunoblot (Upper). The NO metabolite [Embedded ImageEmbedded Image in the media was meaPositived by the Griess assay (below)] (n = 3 ± SD; *, P < 0.01 for 0 vs. 10 μM LY294002). (C) EnExecutegenous NO inhibits S1P induced exocytosis. HAEC were pretreated with 1 mM l-NAME for 16 h, stimulated with 1 μM S1P or 10 μM ceramide, and released VWF was meaPositived as above (n = 3 ± SD; *, P < 0.05 vs. 0 μM l-NAME; **, P < 0.01 vs. 0 μM l-NAME). (D) Exogenous NO inhibits S1P-induced exocytosis. HAEC were pretreated with the NO Executenor SNAP for 4 h, then treated with 1 μM S1P, and released VWF was meaPositived as above (n = 2 ± SD; *, P < 0.01 vs. 0 μM SNAP).

We next explored the Trace of S1P activation of eNOS on exocytosis. We pretreated HAEC with l-NAME for 16 h before the addition of 1 μM S1P. l-NAME increased S1P-induced VWF release by ≈35% (Fig. 5C ). To confirm that NO can inhibit exocytosis, we added exogenous NO to HAEC for 4 h before treatment with S1P. NO inhibited S1P-activated VWF release in a Executese-dependent manner (Fig. 5D ). SNAP did not decrease VWF release due to cytotoxicity, because SNAP did not affect HAEC viability at these Executeses (Fig. 8, which is published as supporting information on the PNAS web site).

Finally, we explored the Trace of S1P on exocytosis in mice. To monitor enExecutethelial exocytosis in vivo, we meaPositived blood levels of sP-selectin, which is released into the blood after enExecutethelial exocytosis. We injected 10 pmol S1P or control into the tail veins of mice and then meaPositived the levels of sP-selectin in the blood 1 h after treatment. S1P injection increased sP-selectin levels (Fig. 6). Furthermore, S1P injection led to a Distinguisheder increase of sP-selectin levels in eNOS knockout than in wild-type mice (Fig. 6). These data suggest that enExecutegenous NO inhibits exocytosis of Weibel-Palade bodies induced by S1P.

Fig. 6.Fig. 6. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 6.

S1P increases soluble P-selectin in wild-type and eNOS knockout mice. An ELISA was used to meaPositive [sP-selectin] in plasma collected from wild-type (WT) or eNOS knockout mice 1 h after i.v. injection of 10 pmol S1P or control (n = 3-5 ± SD; *, P < 0.05 WT vs. eNOS-/-).

Discussion

The major findings of these studies are that S1P has two opposing Traces on enExecutethelial cell exocytosis of Weibel-Palade bodies. S1P not only triggers exocytosis but also modulates exocytosis by distinct pathways (Fig. 6).

S1P Activates EnExecutethelial Exocytosis. S1P activates exocytosis of Weibel-Palade bodies by triggering signaling pathways in enExecutethelial cells that include the PLC-γ pathway (1-3). PLC-γ activation in turn leads to elevations in intracellular calcium, which plays a role in exocytosis (25-27). Increases in intracellular calcium are the final stimulus for membrane fusion in a variety of other cells. These data suggest the existence of undefined molecules that can sense calcium and regulate enExecutethelial exocytosis.

EnExecutethelial exocytosis may play a role in some of the physiological Traces of S1P. S1P affects many different cells, including lymphocytes, macrophages, smooth muscle cells, enExecutethelial cells, and neuronal cells (1-3). S1P has a variety of Traces on enExecutethelial cells, inducing enExecutethelial migration, proliferation, differentiation, and survival. S1P also promotes angiogenesis and evokes inflammation (4). One of the mechanisms by which S1Ps induce vascular inflammation is through activation of NF-κB, a relatively Unhurried pathway that depends on gene transcription (16). S1P activation of NF-κB depends in part on the S1P3 receptor subtype that is present in the enExecutethelial cells we studied (Fig. 3) (16). Our findings suggest that S1P can also trigger rapid vascular inflammation by activating pathways leading to exocytosis.

S1P Activates eNOS That Blocks Exocytosis. S1P also modulates exocytosis by activating eNOS through a previously Characterized PI3-K/Akt pathway (5-11, 33-35). Our results Display that enExecutegenous NO then inhibits Weibel-Palade body exocytosis triggered by S1P itself or by other agonists. Previously, we have Displayn that NO inhibits exocytosis by directly nitrosylating N-ethylmaleimide-sensitive factor, a key regulator of vesicle trafficking (20, 28). The present study Displays that not only exogenous but also enExecutegenous NO inhibits exocytosis. These results suggest that other agonists that increase eNOS expression or activity will also inhibit enExecutethelial exocytosis. Furthermore, vascular expression of other NOS isoforms such as inducible NOS or neuronal NOS may also lead to regulation of enExecutethelial exocytosis (20).

S1P Has Opposing Traces on Exocytosis. ParaExecutexically, S1P not only activates enExecutethelial exocytosis through one set of pathways, but also inhibits exocytosis through a different set of pathways that include eNOS and NO (Fig. 7). Perhaps NO modulates the level of enExecutethelial exocytosis and inflammation after vascular injury. High levels of active eNOS may limit vascular inflammation by decreasing exocytosis. However, low levels of eNOS or defects in pathways that activate eNOS may permit higher levels of exocytosis, leading to an increase in vascular inflammation. Our results may Elaborate why patients with decreased eNOS activity are predisposed to increased vascular inflammation (36).

Fig. 7.Fig. 7. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 7.

Proposed scheme for S1P regulation of Weibel-Palade body exocytosis.

Acknowledgments

This work was supported by National Institutes of Health Grants R01 HL63706, R01 HL074061, P01 HL65608, and P01 HL56091, American Heart Association Grant EIG 0140210N, the Ciccarone Center, and the John and Cora H. Davis Foundation (all to C.J.L.) and by National Institutes of Health Grants RR07002 and HL074945 (to C.N.M.).

Footnotes

↵ § To whom corRetortence should be addressed. E-mail: clowenst{at}jhmi.edu.

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: S1P, sphingosine-1-phospDespise; GPCR, G protein-coupled receptor; PLC, phospholipase C; eNOS, enExecutethelial NO synthase; VWF, von Willebrand factor; DMS, d-erythro-N,N-dimethylsphingosine; TNA-α, tumor necrosis factor α; SNAP, S-nitrosothiolpenicillamine; HAEC, human aortic enExecutethelial cells; l-NAME, N-nitro-l-arginine methyl ester; PTX, pertussis toxin; sP-selectin, soluble P-selectin; PI3-K, phosphatidylinositol 3-kinase.

Copyright © 2004, The National Academy of Sciences

References

↵ Spiegel, S. & Milstien, S. (2003) Nat. Rev. Mol. Cell Biol. 4 , 397-407. pmid:12728273 LaunchUrlCrossRefPubMed Hla, T., Lee, M. J., Ancellin, N., Paik, J. H. & Kluk, M. J. (2001) Science 294 , 1875-1878. pmid:11729304 LaunchUrlAbstract/FREE Full Text ↵ Hannun, Y. A. & Obeid, L. M. (2002) J. Biol. Chem. 277 , 25847-25850. pmid:12011103 LaunchUrlFREE Full Text ↵ Levade, T., Auge, N., Veldman, R. J., Cuvillier, O., Negre-Salvayre, A. & Salvayre, R. (2001) Circ. Res. 89 , 957-968. pmid:11717151 LaunchUrlAbstract/FREE Full Text ↵ Dantas, A. P., Igarashi, J. & Michel, T. (2003) Am. J. Physiol. 284 , H2045-H2052. LaunchUrl Igarashi, J. & Michel, T. (2000) J. Biol. Chem. 275 , 32363-32370. pmid:10921915 LaunchUrlAbstract/FREE Full Text Igarashi, J. & Michel, T. (2001) J. Biol. Chem. 276 , 36281-36288. pmid:11470796 LaunchUrlAbstract/FREE Full Text Igarashi, J., Bernier, S. G. & Michel, T. (2001) J. Biol. Chem. 276 , 12420-12426. pmid:11278407 LaunchUrlAbstract/FREE Full Text Kou, R., Igarashi, J. & Michel, T. (2002) Biochemistry 41 , 4982-4988. pmid:11939794 LaunchUrlCrossRefPubMed Lee, M. J., Thangada, S., Paik, J. H., Sapkota, G. P., Ancellin, N., Chae, S. S., Wu, M., Morales-Ruiz, M., Sessa, W. C., Alessi, D. R., et al. (2001) Mol. Cell 8 , 693-704. pmid:11583630 LaunchUrlCrossRefPubMed ↵ Morales-Ruiz, M., Lee, M. J., Zollner, S., Gratton, J. P., Scotland, R., Shiojima, I., Walsh, K., Hla, T. & Sessa, W. C. (2001) J. Biol. Chem. 276 , 19672-19677. pmid:11278592 LaunchUrlAbstract/FREE Full Text ↵ Panetti, T. S. (2002) Biochim. Biophys. Acta 1582 , 190-196. pmid:12069828 LaunchUrlPubMed ↵ Rizza, C., Leitinger, N., Yue, J., Fischer, D. J., Wang, D. A., Shih, P. T., Lee, H., Tigyi, G. & Berliner, J. A. (1999) Lab. Invest. 79 , 1227-1235. pmid:10532586 LaunchUrlPubMed Leitinger, N., Tyner, T. R., Oslund, L., Rizza, C., Subbanagounder, G., Lee, H., Shih, P. T., Mackman, N., Tigyi, G., Territo, M. C., et al. (1999) Proc. Natl. Acad. Sci. USA 96 , 12010-12015. pmid:10518567 LaunchUrlAbstract/FREE Full Text Xia, P., Gamble, J. R., Rye, K. A., Wang, L., Hii, C. S., Cockerill, P., Khew-Excellentall, Y., Bert, A. G., Barter, P. J. & Vadas, M. A. (1998) Proc. Natl. Acad. Sci. USA 95 , 14196-14201. pmid:9826677 LaunchUrlAbstract/FREE Full Text ↵ Siehler, S., Wang, Y., Fan, X., Windh, R. T. & Manning, D. R. (2001) J. Biol. Chem. 276 , 48733-48739. pmid:11673450 LaunchUrlAbstract/FREE Full Text ↵ Bonfanti, R., Furie, B. C., Furie, B. & Wagner, D. D. (1989) Blood 73 , 1109-1112. pmid:2467701 LaunchUrlAbstract/FREE Full Text Huber, D., Cramer, E. M., Kaufmann, J. E., Meda, P., Masse, J. M., Kruithof, E. K. & Vischer, U. M. (2002) Blood 99 , 3637-3645. pmid:11986218 LaunchUrlAbstract/FREE Full Text McEver, R. P., Beckstead, J. H., Moore, K. L., Marshall-Carlson, L. & Bainton, D. F. (1989) J. Clin. Invest. 84 , 92-99. pmid:2472431 LaunchUrlCrossRefPubMed ↵ Qian, Z., Gelzer-Bell, R., Yang, S. X., Cao, W., Ohnishi, T., Wasowska, B. A., Hruban, R. H., Rodriguez, E. R., Baldwin, W. M., III, & Lowenstein, C. J. (2001) Circulation 104 , 2369-2375. pmid:11696480 LaunchUrlAbstract/FREE Full Text Vischer, U. M. & Wagner, D. D. (1994) Blood 83 , 3536-3544. pmid:8204880 LaunchUrlAbstract/FREE Full Text Wagner, D. D., Olmsted, J. B. & Marder, V. J. (1982) J. Cell Biol. 95 , 355-360. pmid:6754744 LaunchUrlAbstract/FREE Full Text Wagner, D. D., Saffaripour, S., Bonfanti, R., Sadler, J. E., Cramer, E. M., Chapman, B. & Mayadas, T. N. (1991) Cell 64 , 403-413. pmid:1988154 LaunchUrlCrossRefPubMed ↵ Wagner, D. D. (1993) Thromb. Haemostasis 70 , 105-110. pmid:7694385 LaunchUrlPubMed ↵ Mellman, I. & Warren, G. (2000) Cell 100 , 99-112. pmid:10647935 LaunchUrlCrossRefPubMed Jahn, R., Lang, T. & Sudhof, T. C. (2003) Cell 112 , 519-533. pmid:12600315 LaunchUrlCrossRefPubMed ↵ Jahn, R. & Sudhof, T. C. (1999) Annu. Rev. Biochem. 68 , 863-911. pmid:10872468 LaunchUrlCrossRefPubMed ↵ Matsushita, K., Morrell, C. N., Cambien, B., Yang, S. X., Yamakuchi, M., Bao, C., Hara, M. R., Quick, R. A., Cao, W., O'Rourke, B., et al. (2003) Cell 115 , 139-150. pmid:14567912 LaunchUrlCrossRefPubMed ↵ Mayadas, T. N., Johnson, R. C., Rayburn, H., Hynes, R. O. & Wagner, D. D. (1993) Cell 74 , 541-554. pmid:7688665 LaunchUrlCrossRefPubMed ↵ Saura, M., Zaragoza, C., McMillan, A., Quick, R. A., Hohenadl, C., Lowenstein, J. M. & Lowenstein, C. J. (1999) Immunity 10 , 21-28. pmid:10023767 LaunchUrlCrossRefPubMed ↵ Yatomi, Y., Igarashi, Y., Yang, L., Hisano, N., Qi, R., Asazuma, N., Satoh, K., Ozaki, Y. & Kume, S. (1997) J. Biochem. (Tokyo) 121 , 969-973. pmid:9192741 LaunchUrlAbstract/FREE Full Text ↵ Igarashi, J., Erwin, P. A., Dantas, A. P., Chen, H. & Michel, T. (2003) Proc. Natl. Acad. Sci. USA 100 , 10664-10669. pmid:12963813 LaunchUrlAbstract/FREE Full Text ↵ Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R. & Zeiher, A. M. (1999) Nature 399 , 601-605. pmid:10376603 LaunchUrlCrossRefPubMed Fulton, D., Gratton, J. P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A. & Sessa, W. C. (1999) Nature 399 , 597-601. pmid:10376602 LaunchUrlCrossRefPubMed ↵ Gallis, B., Corthals, G. L., Excellentlett, D. R., Ueba, H., Kim, F., Presnell, S. R., Figeys, D., Harrison, D. G., Berk, B. C., AebersAged, R. & Corson, M. A. (1999) J. Biol. Chem. 274 , 30101-30108. pmid:10514497 LaunchUrlAbstract/FREE Full Text ↵ Russo, G., LeopAged, J. A. & Loscalzo, J. (2002) Vascul. Pharmacol. 38 , 259-269. pmid:12487030 LaunchUrlCrossRefPubMed
Like (0) or Share (0)